Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences: National Black HIV/AIDS Awareness Day

ACCESS Newswire February 29, 2024

Gilead Announces Funding Initiative To Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

ACCESS Newswire February 28, 2024

Gilead Announces Funding Initiative to Support HIV Prevention, Anti-Stigma and Health Equity Efforts for Black Cisgender and Transgender Women and Girls in the U.S.

Business Wire February 27, 2024

U.S. FDA Approves Expanded Indication for Gilead's Biktarvy® to Treat People with HIV with Suppressed Viral Loads, Pre-existing Resistance

Business Wire February 26, 2024

Gilead to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline at CROI 2024

Business Wire February 26, 2024

Gilead Sciences and Black HIV/AIDS Awareness Day: Taking Action Toward Meaningful Change

ACCESS Newswire February 26, 2024

Gilead Sciences to Present at Upcoming Investor Conferences

Business Wire February 20, 2024

Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC

ACCESS Newswire February 20, 2024

Gilead Sets Sights on Hepatitis C Elimination As It Marks 10 Years of Curative Therapies

ACCESS Newswire February 13, 2024

Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics

Business Wire February 12, 2024

Gilead Named One of America's Most JUST Companies by JUST Capital and CNBC

Business Wire February 9, 2024

Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2024 Dividend

Business Wire February 6, 2024

Gilead Sciences Announces Fourth Quarter and Full Year 2023 Financial Results

Business Wire February 6, 2024

Gilead Named One of Newsweek America's Greatest Workplaces for Diversity

ACCESS Newswire February 6, 2024

Ted Love, MD, Joins Gilead Sciences' Board of Directors

Business Wire February 1, 2024

Kite Receives U.S. FDA Approval of Manufacturing Process Change Resulting in Reduced Median Turnaround Time for Yescarta® CAR T-cell Therapy

Business Wire January 30, 2024

From the Margins: Gilead's Book Uniquely Captures What It's Like To Be Marginalized by Disease

ACCESS Newswire January 30, 2024

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Business Wire January 29, 2024

Gilead Sciences to Release Fourth Quarter & Full Year 2023 Financial Results on Tuesday, February 6, 2024

Business Wire January 23, 2024

Gilead Sciences: Art Captures the Experiences of Women Living With Metastatic Breast Cancer

ACCESS Newswire January 23, 2024